Valuation: Evotec SE

Capitalization 84Cr 98Cr 77Cr 73Cr 134.45Cr 9.46TCr 137.83Cr 919.76Cr 358.18Cr 4.45TCr 366.57Cr 358.76Cr 16TCr P/E ratio 2026 *
-5.79x
P/E ratio 2027 * -24.3x
Enterprise value 86Cr 99Cr 78Cr 74Cr 136.73Cr 9.62TCr 140.17Cr 935.37Cr 364.26Cr 4.53TCr 372.79Cr 364.85Cr 16TCr EV / Sales 2026 *
1.16x
EV / Sales 2027 * 1.11x
Free-Float
89.96%
Yield 2026 *
-
Yield 2027 * -
1 day+0.64%
1 week-6.69%
Current month-9.54%
1 month-15.96%
3 months-22.45%
6 months-8.18%
Current year-13.03%
1 week 4.57
Extreme 4.57
4.88
1 month 4.43
Extreme 4.432
5.79
Current year 4
Extreme 3.995
6.73
1 year 4
Extreme 3.995
8.57
3 years 4
Extreme 3.995
24.44
5 years 4
Extreme 3.995
45.83
10 years 3.1
Extreme 3.1
45.83
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Chairman 65 15/06/2021
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Change 5d. change 1-year change 3-years change Capi.($)
+0.64%-6.69%-32.36%-75.95% 97Cr
+4.21%+2.07%-15.01%-15.57% 4.16TCr
+1.34%-5.73%+27.27%+27.69% 3.26TCr
+2.03%+1.08%+268.90%+469.83% 3.07TCr
+0.21%-1.07%+20.65%-13.17% 2.88TCr
-0.38%-5.59%+23.25%+14.60% 2.57TCr
+0.14%+0.14% - - 1.48TCr
-2.84%+2.47%+191.46%+4,084.10% 1.37TCr
+1.82%-2.62%+116.99%+88.42% 1.2TCr
+2.03%+3.55%+9.70%+1.36% 1.23TCr
Average +0.92%-1.74%+67.87%+509.03% 2.13TCr
Weighted average by Cap. +1.35%-1.89%+69.71%+361.90%

Financials

2026 *2027 *
Net sales 74Cr 86Cr 68Cr 64Cr 117.71Cr 8.28TCr 120.67Cr 805.22Cr 313.57Cr 3.9TCr 320.92Cr 314.08Cr 14TCr 82Cr 95Cr 75Cr 71Cr 130.51Cr 9.18TCr 133.79Cr 892.78Cr 347.68Cr 4.32TCr 355.82Cr 348.24Cr 15TCr
Net income -13Cr -15Cr -11Cr -11Cr -20Cr -1.41TCr -20Cr -136.67Cr -53Cr -661.53Cr -54Cr -53Cr -2.31TCr -3.04Cr -3.53Cr -2.79Cr -2.63Cr -4.85Cr -341.48Cr -4.98Cr -33Cr -13Cr -160.75Cr -13Cr -13Cr -561.34Cr
Net Debt 1.43Cr 1.66Cr 1.31Cr 1.24Cr 2.28Cr 160.52Cr 2.34Cr 16Cr 6.08Cr 76Cr 6.22Cr 6.09Cr 263.86Cr 6.93Cr 8.04Cr 6.35Cr 6Cr 11Cr 778.17Cr 11Cr 76Cr 29Cr 366.33Cr 30Cr 30Cr 1.28TCr
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,526
Date Price Change Volume
19/26/19 4.740 +0.64% 8,57,146
18/26/18 4.710 +1.99% 6,05,664
15/26/15 4.618 -1.74% 6,04,386
14/26/14 4.700 +3.52% 8,69,582
13/26/13 4.540 -10.63% 28,29,363
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.740EUR
Average target price
6.443EUR
Spread / Average Target
+35.93%

Quarterly revenue - Rate of surprise